SG11201405276PA - Xten conjugate compositions and methods of making same - Google Patents

Xten conjugate compositions and methods of making same

Info

Publication number
SG11201405276PA
SG11201405276PA SG11201405276PA SG11201405276PA SG11201405276PA SG 11201405276P A SG11201405276P A SG 11201405276PA SG 11201405276P A SG11201405276P A SG 11201405276PA SG 11201405276P A SG11201405276P A SG 11201405276PA SG 11201405276P A SG11201405276P A SG 11201405276PA
Authority
SG
Singapore
Prior art keywords
methods
making same
conjugate compositions
xten conjugate
xten
Prior art date
Application number
SG11201405276PA
Inventor
Volker Schellenberger
Vladimir Podust
Chia-Wei Wang
Bryant Mclaughlin
Bee-Cheng Sim
Sheng Ding
Chen Gu
Original Assignee
Amunix Operating Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Operating Inc filed Critical Amunix Operating Inc
Publication of SG11201405276PA publication Critical patent/SG11201405276PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
SG11201405276PA 2012-02-27 2013-02-27 Xten conjugate compositions and methods of making same SG11201405276PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261634312P 2012-02-27 2012-02-27
US201261690187P 2012-06-18 2012-06-18
US201261709942P 2012-10-04 2012-10-04
PCT/US2013/028116 WO2013130683A2 (en) 2012-02-27 2013-02-27 Xten conjugate compositions and methods of making same

Publications (1)

Publication Number Publication Date
SG11201405276PA true SG11201405276PA (en) 2014-10-30

Family

ID=49083255

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201405276PA SG11201405276PA (en) 2012-02-27 2013-02-27 Xten conjugate compositions and methods of making same
SG10201700340WA SG10201700340WA (en) 2012-02-27 2013-02-27 Xten conjugate compositions and methods of making same

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201700340WA SG10201700340WA (en) 2012-02-27 2013-02-27 Xten conjugate compositions and methods of making same

Country Status (17)

Country Link
US (4) US10172953B2 (en)
EP (2) EP2819788B1 (en)
JP (5) JP6355563B2 (en)
KR (1) KR102057356B1 (en)
CN (3) CN107496932A (en)
AU (2) AU2013226090B2 (en)
CA (2) CA3179537A1 (en)
CL (1) CL2014002277A1 (en)
EA (2) EA030911B1 (en)
HK (1) HK1200139A1 (en)
IL (2) IL234309B (en)
MX (2) MX366864B (en)
PE (1) PE20142451A1 (en)
PH (1) PH12014501924A1 (en)
SG (2) SG11201405276PA (en)
WO (2) WO2013130684A1 (en)
ZA (2) ZA201406339B (en)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ593833A (en) * 2009-02-03 2013-10-25 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
MX366864B (en) * 2012-02-27 2019-07-26 Amunix Operating Inc Xten conjugate compositions and methods of making same.
WO2014100913A1 (en) * 2012-12-24 2014-07-03 Beijing Anxinhuaide Biotech. Co., Ltd Improving the half life of a therapeutic polypeptide by fusing with a trimeric scaffold protein via a spacer
US9289502B2 (en) * 2013-03-08 2016-03-22 Emerald Therapeutics, Inc. Preparation of oligo conjugates
EP2979702A4 (en) * 2013-03-25 2016-11-16 Zeria Pharm Co Ltd Postprandial gastrokinetic agent
JP6822839B2 (en) 2013-09-13 2021-01-27 ザ・スクリップス・リサーチ・インスティテュート Modified therapeutic agents and their compositions
EP3082797A4 (en) 2013-12-18 2017-12-13 The California Institute for Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EP3089745A4 (en) 2013-12-31 2017-05-17 Placon Therapeutics, Inc. Compounds, compositions, and methods for the treatment of cancers
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
EP3797768A1 (en) 2014-06-23 2021-03-31 Placon Therapeutics, Inc. Maleimide-functionalised platinum for use in the treatment of cancer
CN106573077B (en) * 2014-06-30 2019-07-30 塔弗达治疗有限公司 Target conjugate and its particle and preparation
US20170281732A1 (en) * 2014-08-19 2017-10-05 Oxeia Biopharmaceuticals, Inc. Methods of treating mild brain injury
SG11201702122RA (en) * 2014-09-16 2017-04-27 Univ Western Australia Treatment of tumours using peptide-protein conjugates
US20170266257A1 (en) * 2014-09-25 2017-09-21 Oxeia Biopharmaceuticals, Inc. Methods of treating traumatic brain injury
EP3218390A4 (en) * 2014-11-11 2018-11-21 Amunix Operating Inc. Targeted xten conjugate compositions and methods of making same
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
WO2016132366A1 (en) 2015-02-18 2016-08-25 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
LT3283508T (en) 2015-04-17 2021-07-12 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
EP3613756B1 (en) * 2015-04-28 2024-02-21 Hybio Pharmaceutical Co., Ltd. High performance liquid chromatography method for polypeptide mixtures
WO2016193380A1 (en) 2015-06-02 2016-12-08 Novo Nordisk A/S Insulins with polar recombinant extensions
EP3328998A1 (en) * 2015-07-27 2018-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Mutated factor x polypeptides and uses thereof for the treatment of haemophilia
MX2018001723A (en) * 2015-08-11 2018-05-17 Coherent Biopharma Multi-ligand drug conjugates and uses thereof.
EP4129327A1 (en) 2015-08-28 2023-02-08 Amunix Pharmaceuticals, Inc. Chimeric polypeptide assembly and methods of making and using the same
CN108135857A (en) 2015-09-10 2018-06-08 沙思奇公司 bio-orthogonal composition
MA43348A (en) * 2015-10-01 2018-08-08 Novo Nordisk As PROTEIN CONJUGATES
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
EP3368546A4 (en) 2015-10-28 2019-06-26 Tarveda Therapeutics, Inc. Sstr-targeted conjugates and particles and formulations thereof
US20170145394A1 (en) 2015-11-23 2017-05-25 The Regents Of The University Of California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
HRP20211466T1 (en) * 2015-12-09 2021-12-24 Medizinische Universität Wien Monomaleimide-functionalized platinum compounds for cancer therapy
CA3009880A1 (en) * 2015-12-28 2017-07-06 Idemitsu Kosan Co., Ltd. Peptide tag and tagged protein including same
CN113546159B (en) 2015-12-29 2023-09-08 派格生物医药(苏州)股份有限公司 Compositions comprising GLP-1 receptor agonists and glucagon receptor agonists and uses thereof
KR20180110141A (en) 2016-02-18 2018-10-08 엔리벡스 테라퓨틱스 리미티드 Combination of immunotherapy and cytokine regulating therapy to treat cancer
AR107560A1 (en) * 2016-02-24 2018-05-09 Lilly Co Eli COMPOUND THAT DECREASES GLUCOSE IN BLOOD
KR20190015210A (en) * 2016-03-30 2019-02-13 퀄리자임 다이아그노스틱스 게엠베하 엔드 코 카게 Detection of microbial infection in wound
CA3019202A1 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
MX2018012472A (en) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof.
WO2017197048A1 (en) * 2016-05-11 2017-11-16 Amunix Operating Inc. Albumin binding conjugate compositions and methods of making and using same
EP3465221B1 (en) 2016-05-27 2020-07-22 H. Hoffnabb-La Roche Ag Bioanalytical method for the characterization of site-specific antibody-drug conjugates
KR102590454B1 (en) 2016-07-07 2023-10-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Antibody-Adjuvant Conjugate
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
KR20190099194A (en) 2016-10-20 2019-08-26 알파인 이뮨 사이언시즈, 인코포레이티드 Secretory variant immunomodulatory proteins and engineered cell therapy
WO2018170026A2 (en) 2017-03-16 2018-09-20 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
EP3596115A1 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Pd-l2 variant immunomodulatory proteins and uses thereof
HRP20231382T1 (en) 2017-03-16 2024-02-16 Alpine Immune Sciences, Inc. Pd-l1 variant immunomodulatory proteins and uses thereof
JP2020513019A (en) 2017-04-05 2020-04-30 ノヴォ ノルディスク アー／エス Oligomer-extended insulin-Fc conjugate
CN111093708A (en) 2017-04-07 2020-05-01 坦伯公司 Bioorthogonal compositions
EP3622062A4 (en) 2017-05-10 2020-10-14 The Regents of the University of California Directed editing of cellular rna via nuclear delivery of crispr/cas9
KR20200030065A (en) 2017-06-21 2020-03-19 재즈 파마슈티칼즈 아일랜드 리미티드 Modified L-asparaginase
EP3418383A1 (en) 2017-06-21 2018-12-26 XL-protein GmbH Modified l-asparaginase
US10889627B2 (en) * 2017-06-29 2021-01-12 Ureka Sarl Pro-drug peptide with improved pharmaceutical properties
JP2019043946A (en) * 2017-08-31 2019-03-22 国立大学法人埼玉大学 Ligand for molecule purification, tag peptide for molecule purification, and molecule purification method using the same
CN111801347A (en) 2017-10-10 2020-10-20 高山免疫科学股份有限公司 CTLA-4 variant immunomodulatory proteins and uses thereof
AU2018351000B2 (en) 2017-10-18 2023-11-30 Alpine Immune Sciences, Inc. Variant ICOS Ligand immunomodulatory proteins and related compositions and methods
JP2021502418A (en) * 2017-11-04 2021-01-28 アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド Compositions and Methods for Modifying Polypeptides
US20200385469A1 (en) * 2017-12-21 2020-12-10 Amunix Pharmaceuticals, Inc. Release segments and binding compositions comprising same
AU2019205273B2 (en) 2018-01-03 2024-04-04 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
KR102113588B1 (en) * 2018-03-26 2020-05-22 (주)터틀바이오 Mass Production System of Oligopeptide with His-Pro Repeats
US20210363219A1 (en) 2018-06-15 2021-11-25 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
WO2019241609A1 (en) * 2018-06-15 2019-12-19 Trustees Of Boston University Polypeptide compositions and methods for site-specific targeting of therapeutic agents
AU2019345151A1 (en) 2018-09-19 2021-04-29 Alpine Immune Sciences, Inc. Methods and uses of variant CD80 fusion proteins and related constructs
BR112021005907A2 (en) 2018-09-27 2021-08-10 Xilio Development, Inc. masked cytokines, nucleic acid, vector, host cell, methods for producing a masked cytokine, for treating or preventing a neoplastic disease and for treating or preventing a neoplastic inflammatory or autoimmune disease, composition, pharmaceutical composition and kit
EP3864024A4 (en) * 2018-10-10 2022-07-06 University of Washington Fusion products and bioconjugates containing mixed charge peptides
MA54070A (en) 2018-10-29 2021-09-08 Biogen Ma Inc HUMANIZED AND STABILIZED FC5 VARIANTS FOR ENHANCED TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER
CN111153965A (en) * 2018-11-07 2020-05-15 浙江道尔生物科技有限公司 Artificial recombinant protein for improving performance of active protein or polypeptide and application thereof
JP2022510276A (en) 2018-11-30 2022-01-26 アルパイン イミューン サイエンシズ インコーポレイテッド CD86 variant immunomodulatory protein and its use
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
US20220218785A1 (en) 2019-04-17 2022-07-14 Alpine Immune Sciences, Inc. Methods and uses of variant icos ligand (icosl) fusion proteins
EP3757217A1 (en) * 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Methods for protein purification
AU2020345138A1 (en) * 2019-09-13 2022-04-21 Biological E Limited N-terminal extension sequence for expression of recombinant therapeutic peptides
CN113597434B (en) 2019-12-31 2022-07-01 北京质肽生物医药科技有限公司 Fusion proteins of GLP-1 and GDF15 and conjugates thereof
CN115322794A (en) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Conjugates of fusion proteins of GLP-1 and FGF21
WO2021226553A2 (en) 2020-05-08 2021-11-11 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
AU2021267940A1 (en) 2020-05-08 2022-12-08 President And Fellows Of Harvard College Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
WO2021262985A1 (en) * 2020-06-25 2021-12-30 Amunix Pharmaceuticals, Inc. Cytokine conjugates
AU2021335509A1 (en) 2020-09-04 2023-03-09 F. Hoffmann-La Roche Ag Antibody that binds to VEGF-A and ANG2 and methods of use
TW202228784A (en) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 Compound for the sequestration of undesirale anti-peg antibodies in a patient
JP2023545684A (en) 2020-09-30 2023-10-31 ベイジン キューエル バイオファーマシューティカル カンパニー，リミテッド Polypeptide conjugates and methods of use
KR20230087538A (en) * 2020-10-16 2023-06-16 엠펙 엘에이, 엘.엘.씨. Linker compound containing an amide bond
TWI815194B (en) 2020-10-22 2023-09-11 美商基利科學股份有限公司 INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE
CN112362797B (en) * 2020-10-26 2022-05-27 浙江国正检测技术有限公司 Method for detecting quinolone drugs in feed
AU2021409801A1 (en) 2020-12-21 2023-06-22 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
EP4267592A1 (en) * 2020-12-23 2023-11-01 Jazz Pharmaceuticals Ireland Ltd. Methods of purifying charge-shielded fusion proteins
EP4333869A1 (en) 2021-05-07 2024-03-13 Alpine Immune Sciences, Inc. Methods of dosing and treatment with a taci-fc fusion immunomodulatory protein
CN113671085B (en) * 2021-08-30 2023-03-03 珠海润都制药股份有限公司 Method for detecting 2-azido-3-methylbutyric acid in valsartan
CN113845585A (en) * 2021-11-08 2021-12-28 浙江毓昌生物技术有限公司 Method for removing recombinant human growth hormone endotoxin by using metal chelate chromatography
WO2023172883A1 (en) 2022-03-07 2023-09-14 Alpine Immune Sciences, Inc. Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
WO2023212294A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Angiopoietin-related protein 7-specific antibodies and uses thereof
WO2023212298A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Bispecific antibodies and methods of treating ocular disease
WO2023212293A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Complement factor h related 4-specific antibodies and uses thereof
CN116063387B (en) * 2022-07-12 2023-11-24 东北农业大学 Proline protection type enzymolysis-resistant antibacterial peptide and preparation method and application thereof
CN115819513B (en) * 2022-07-25 2023-10-17 东北农业大学 Lauric acid modified enzymolysis-resistant peptide and preparation method and application thereof

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4398908A (en) 1980-11-28 1983-08-16 Siposs George G Insulin delivery system
US4435173A (en) 1982-03-05 1984-03-06 Delta Medical Industries Variable rate syringe pump for insulin delivery
DK27885A (en) 1985-01-22 1986-07-23 Novo Industri As PREPARATION OF PEPTIDES
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US4933185A (en) 1986-09-24 1990-06-12 Massachusetts Institute Of Technology System for controlled release of biologically active compounds
US4976696A (en) 1987-08-10 1990-12-11 Becton, Dickinson And Company Syringe pump and the like for delivering medication
US5182375A (en) 1987-08-28 1993-01-26 The Salk Institute For Biological Studies DNA encoding follistatin
US5041538A (en) 1987-08-28 1991-08-20 The Salk Institute For Biological Studies Mammalian follistatin
US5270176A (en) 1987-11-20 1993-12-14 Hoechst Aktiengesellschaft Method for the selective cleavage of fusion proteins with lysostaphin
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
JP2717808B2 (en) 1988-08-10 1998-02-25 テルモ株式会社 Syringe pump
US6225449B1 (en) 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
US5017378A (en) 1989-05-01 1991-05-21 The University Of Virginia Alumni Patents Foundation Intraorgan injection of biologically active compounds contained in slow-release microcapsules or microspheres
US5599907A (en) 1989-05-10 1997-02-04 Somatogen, Inc. Production and use of multimeric hemoglobins
US5298022A (en) 1989-05-29 1994-03-29 Amplifon Spa Wearable artificial pancreas
US5318540A (en) 1990-04-02 1994-06-07 Pharmetrix Corporation Controlled release infusion device
US5492534A (en) 1990-04-02 1996-02-20 Pharmetrix Corporation Controlled release portable pump
US5176502A (en) 1990-04-25 1993-01-05 Becton, Dickinson And Company Syringe pump and the like for delivering medication
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
NZ265452A (en) 1993-03-29 1997-09-22 Univ Cincinnati Analogues of peptide yy, dimers and pharmaceutical compositions
US5545616A (en) 1994-09-22 1996-08-13 Genentech, Inc. Method for predicting and/or preventing preterm labor
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US5574010A (en) 1994-11-14 1996-11-12 The Regents Of The University Of California Treatment of pancreatic tumors with peptide YY and analogs thereof
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5789379A (en) 1995-04-14 1998-08-04 Allelix Biopharmaceutical Inc. Glucagon-like peptide-2 analogs
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5830655A (en) 1995-05-22 1998-11-03 Sri International Oligonucleotide sizing using cleavable primers
SE9503380D0 (en) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
CA2237114A1 (en) 1995-11-07 1997-05-15 Kaneka Corporation Autoantigens
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
CN1304058C (en) 1996-03-12 2007-03-14 Pg－Txl有限公司 Water soluble paclitaxel prodrugs
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
US20020025933A1 (en) 1996-08-30 2002-02-28 Knudsen Liselotte Bjerre GLP-2 derivatives
WO1998026095A1 (en) 1996-12-10 1998-06-18 Genetrace Systems Inc. Releasable nonvolatile mass-label molecules
AT405516B (en) 1997-02-27 1999-09-27 Immuno Ag FACTOR X-ANALOG WITH MODIFIED PROTEASE SPLIT
JP2002512624A (en) 1997-05-21 2002-04-23 バイオベーション リミテッド Method for producing non-immunogenic protein
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
IL136349A0 (en) 1997-11-25 2001-05-20 Gen Hospital Corp Virulence-associated nucleic acid sequences and uses thereof
DE69838526T2 (en) 1998-02-05 2008-07-03 Biosense Webster, Inc., Diamond Bar Device for releasing a drug in the heart
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
PL196533B1 (en) 1998-04-28 2008-01-31 Applied Research Systems Method for the stepwise attachment of polyethylene glycol (peg) in series to polypeptide
US7090976B2 (en) 1999-11-10 2006-08-15 Rigel Pharmaceuticals, Inc. Methods and compositions comprising Renilla GFP
GB9815157D0 (en) 1998-07-13 1998-09-09 Metron Designs Ltd High resolution pulse width setting from relatively low frequency clocks
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
WO2000034317A2 (en) 1998-12-08 2000-06-15 Biovation Limited Method for reducing immunogenicity of proteins
US7666400B2 (en) 2005-04-06 2010-02-23 Ibc Pharmaceuticals, Inc. PEGylation by the dock and lock (DNL) technique
CA2696819C (en) 1999-07-23 2015-07-07 Kenji Kangawa Ghrelin related peptides
US20030109428A1 (en) 1999-12-01 2003-06-12 John Bertin Novel molecules of the card-related protein family and uses thereof
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
WO2001092292A2 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Ghrelin analogs
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
US20030228309A1 (en) 2000-11-08 2003-12-11 Theodora Salcedo Antibodies that immunospecifically bind to TRAIL receptors
US20030049689A1 (en) 2000-12-14 2003-03-13 Cynthia Edwards Multifunctional polypeptides
PE20020908A1 (en) 2001-03-21 2002-10-26 Cell Therapeutics Inc RECOMBINANT PRODUCTION OF POLYANIONIC POLYMERS AND USE OF THE SAME
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
KR100407467B1 (en) 2001-07-12 2003-11-28 최수봉 Insulin pump operated by remote-controller
WO2003011213A2 (en) 2001-07-30 2003-02-13 Eli Lilly And Company Method for treating diabetes and obesity
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
US7524821B2 (en) 2002-06-20 2009-04-28 University Of Maryland Biotechnology Institute Scaffolded maleimide clusters for multivalent peptide assembly
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
US20050032081A1 (en) 2002-12-13 2005-02-10 Jingyue Ju Biomolecular coupling methods using 1,3-dipolar cycloaddition chemistry
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
WO2004104020A2 (en) 2003-05-14 2004-12-02 Dow Corning Corporation Repeat sequence protein polymer active agent conjugates, methods and uses
US20070161087A1 (en) 2003-05-29 2007-07-12 Wolfgang Glaesner Glp-1 fusion proteins
US7498024B2 (en) 2003-06-03 2009-03-03 Cell Genesys, Inc. Compositions and methods for enhanced expression of immunoglobulins from a single vector using a peptide cleavage site
US20050152979A1 (en) 2003-09-05 2005-07-14 Cell Therapeutics, Inc. Hydrophobic drug compositions containing reconstitution enhancer
US20070203058A1 (en) 2003-09-19 2007-08-30 Novo Nordisk A/S Novel Glp-1 Derivatives
WO2005046583A2 (en) 2003-10-30 2005-05-26 Emory University Modified fviii having reduced immunogenicity through mutagenesis of a2 and c2 epitopes
US20060148680A1 (en) 2004-01-14 2006-07-06 Kieliszewski Marcia J Glycoproteins produced in plants and methods of their use
PL1729795T3 (en) 2004-02-09 2016-08-31 Human Genome Sciences Inc Albumin fusion proteins
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP3059245B1 (en) 2004-07-23 2018-11-07 Acceleron Pharma Inc. Actrii receptor antagonistic antibodies
EP1797127B1 (en) 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
US20060099710A1 (en) * 2004-11-10 2006-05-11 Donnelly Mark I Vector for improved in vivo production of proteins
JP5735194B2 (en) 2005-01-25 2015-06-17 セル セラピューティクス インコーポレーテッド Biologically active protein with improved in vivo half-life
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
ATE498631T1 (en) 2005-05-04 2011-03-15 Zealand Pharma As GLUCAGON LIKE PEPTIDE 2 (GLP-2) ANALOGUE
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
DK2402754T4 (en) 2006-03-06 2023-08-28 Amunix Operating Inc Unstructured recombinant polymers and uses thereof
EP2010222A1 (en) 2006-03-31 2009-01-07 Baxter International Inc. Pegylated factor viii
WO2007130535A2 (en) 2006-05-04 2007-11-15 Molecular Innovations Novel protein fusion/tag technology
KR101454508B1 (en) * 2006-05-30 2014-11-04 제넨테크, 인크. Antibodies and immunoconjugates and uses therefor
WO2008052187A2 (en) 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
WO2008049711A1 (en) 2006-10-27 2008-05-02 Novo Nordisk A/S Peptide extended insulins
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
JP2010536341A (en) 2007-08-15 2010-12-02 アムニクス， インコーポレイテッド Compositions and methods for altering properties of biologically active polypeptides
CN102131516B (en) 2008-06-27 2016-03-16 杜克大学 Comprise the therapeutic agent of elastin-like peptides
US8957021B2 (en) 2009-02-03 2015-02-17 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
NZ593833A (en) 2009-02-03 2013-10-25 Amunix Operating Inc Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) * 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN106916229A (en) 2009-06-08 2017-07-04 阿穆尼克斯运营公司 Growth hormone polypeptides and its preparation and application
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
EP3222287A1 (en) 2009-08-24 2017-09-27 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
CA2779099C (en) 2009-10-30 2021-08-10 Northwestern University Templated nanoconjugates
US20110312881A1 (en) 2009-12-21 2011-12-22 Amunix, Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
US8557961B2 (en) 2010-04-02 2013-10-15 Amunix Operating Inc. Alpha 1-antitrypsin compositions and methods of making and using same
WO2011123813A2 (en) * 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
US8859629B2 (en) 2010-04-27 2014-10-14 Synaffix B.V. Fused cyclooctyne compounds and their use in metal-free click reactions
SI2571510T1 (en) * 2010-05-21 2019-02-28 Xl-Protein Gmbh Biosynthetic proline/alanine random coil polypeptides and their uses
US20130017997A1 (en) 2010-08-19 2013-01-17 Amunix Operating Inc. Factor VIII Compositions and Methods of Making and Using Same
PT2755675T (en) 2011-09-12 2018-10-11 Amunix Operating Inc Glucagon-like peptide-2 compositions and methods of making and using same
ES2771208T3 (en) 2012-02-15 2020-07-06 Bioverativ Therapeutics Inc Factor VIII compositions and methods of preparation and use thereof
MX366864B (en) 2012-02-27 2019-07-26 Amunix Operating Inc Xten conjugate compositions and methods of making same.
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure

Also Published As

Publication number Publication date
MX2019008494A (en) 2019-09-18
JP2022069495A (en) 2022-05-11
CN104302408A (en) 2015-01-21
CA2865578A1 (en) 2013-09-06
US20190083577A1 (en) 2019-03-21
CL2014002277A1 (en) 2015-06-12
MX366864B (en) 2019-07-26
CN104302408B (en) 2016-12-14
US20150037359A1 (en) 2015-02-05
CN117462693A (en) 2024-01-30
AU2013226090A1 (en) 2014-09-18
PH12014501924A1 (en) 2014-11-24
ZA201406339B (en) 2018-12-19
US20240091315A1 (en) 2024-03-21
JP2018127496A (en) 2018-08-16
CA2865578C (en) 2023-01-17
AU2018201441B2 (en) 2020-01-30
CA3179537A1 (en) 2013-09-06
CN107496932A (en) 2017-12-22
PE20142451A1 (en) 2015-02-04
JP6355563B2 (en) 2018-07-11
KR102057356B1 (en) 2019-12-18
EA201491441A1 (en) 2015-07-30
MX2014010348A (en) 2015-08-20
EP3406347A2 (en) 2018-11-28
HK1200139A1 (en) 2015-07-31
IL265327A (en) 2019-05-30
EP2819788A4 (en) 2016-02-10
WO2013130683A3 (en) 2014-12-11
BR112014021256A2 (en) 2017-07-04
EA201890389A2 (en) 2018-07-31
EP2819788A2 (en) 2015-01-07
EA030911B1 (en) 2018-10-31
WO2013130684A1 (en) 2013-09-06
JP2018130123A (en) 2018-08-23
AU2018201441A1 (en) 2018-03-22
US20210322518A1 (en) 2021-10-21
SG10201700340WA (en) 2017-03-30
EA037979B1 (en) 2021-06-18
US10953073B2 (en) 2021-03-23
AU2013226090B2 (en) 2018-03-08
EP2819788B1 (en) 2018-08-22
WO2013130683A2 (en) 2013-09-06
JP2015514393A (en) 2015-05-21
KR20140136008A (en) 2014-11-27
JP2020114234A (en) 2020-07-30
US10172953B2 (en) 2019-01-08
EA201890389A3 (en) 2018-11-30
IL234309B (en) 2020-06-30
ZA201801246B (en) 2019-05-29
EP3406347A3 (en) 2019-02-13

Similar Documents

Publication Publication Date Title
IL265327A (en) Xten conjugate compositions and methods of making same
AU2018250410A1 (en) Factor viii compositions and methods of making and using same
HK1204330A1 (en) Factor viii compositions and methods of making and using same viii
HK1207001A1 (en) Immunostimulatory compositions and methods of use thereof
EP2836224A4 (en) Compositions of microbiota and methods related thereto
EP2895559A4 (en) Bitumen compositions and methods of making
HK1175947A1 (en) Pharmaceutical compositions and methods of making same
SG11201405268PA (en) Lubricant composition of matter and methods of preparation
HK1207824A1 (en) Polymorph compositions, methods of making, and uses thereof
HK1209031A1 (en) Polysaccharide compositions and methods of use
HK1216891A1 (en) Bryoid compositions, methods of making and use thereof
EP2838543A4 (en) Immunostimulatory compositions and methods of manufacture
AU2012905317A0 (en) Methods and Preparation and Use of Xanthorrhoeaceae Compositions
AU2012901658A0 (en) Compositions and methods of use
EP2841164A4 (en) Dermal-appropriate compositions and methods of use